Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Clonazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 5/20 | 0.74 |
| ▸ | GABRA5 known ✓ | P31644 | 5/20 | 0.74 |
| ▸ | GABRA3 known ✓ | P34903 | 5/20 | 0.74 |
| ▸ | GABRA2 known ✓ | P47869 | 5/20 | 0.74 |
| ▸ | GABRB2 known ✓ | P47870 | 4/20 | 0.74 |
| ▸ | GABRG2 known ✓ | P18507 | 4/20 | 0.74 |
| ▸ | GABRB3 known ✓ | P28472 | 4/20 | 0.74 |
| ▸ | GABRP known ✓ | O00591 | 3/20 | 0.74 |
| ▸ | GABRD known ✓ | O14764 | 3/20 | 0.74 |
| ▸ | GABRB1 known ✓ | P18505 | 3/20 | 0.74 |
| ▸ | GABRA4 known ✓ | P48169 | 3/20 | 0.74 |
| ▸ | GABRE known ✓ | P78334 | 3/20 | 0.74 |
| ▸ | GABRA6 known ✓ | Q16445 | 3/20 | 0.74 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 3/20 | 0.74 |
| ▸ | GABRG3 known ✓ | Q99928 | 3/20 | 0.74 |
| ▸ | GABRQ known ✓ | Q9UN88 | 3/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clonazepam SCHEMBL13746712 | 0.86 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL5501860 | 0.86 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL29361251 | 0.86 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL38899 | 0.86 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL29369721 | 0.86 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL29743048 | 0.86 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL13747803 | 0.86 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL9834407 | 0.85 | GABRA1 (0.98) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL31321724 | 0.85 | GABRA1 (0.98) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL28390843 | 0.85 | GABRA1 (0.98) | GABRA1GABRA5GABRA3GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1210076-A2 | DRUG THERAPY OF THE RESTLESS LEG SYNDROME | Boehringer Ingelheim Pharma KG (DE) | 2002-06-05 | — | — | EP | claimed |
| WO-2001013903-A2 | TREATMENT OF RESTLESS LEG SYNDROME WITH A COMBINATION OF CLONIDINE AND OPIOID | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-03-01 | — | — | WO | claimed |
| EP-0532546-B1 | A PHARMACEUTICAL PREPARATION CONTAINING N-GLYCOFUROLS AND N-ETHYLENE GLYCOLS | BECHGAARD INT RES (DK) | 1998-03-18 | — | — | EP | claimed |
| US-11986446-B2 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-05-21 | — | — | US | disclosed |
| US-20220193015-A1 | METHOD OF ADMINISTRATION OF GAMMA HYDROXYBUTYRATE WITH MONOCARBOXYLATE TRANSPORTERS | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2022-06-23 | — | — | US | disclosed |
| US-11253494-B2 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2022-02-22 | — | — | US | disclosed |
| US-20210236507-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING RELAPSE IN A PERSON WITH AN ADDICTION USING BETA ADRENERGIC RECEPTOR ANTAGONIST AND MUSCARINIC RECEPTOR ANTAGONIST COMBINATIONS | MAGNOLIA CNS, LLC | 2021-08-05 | — | — | US | disclosed |
| US-20210212970-A1 | METHOD OF ADMINISTRATION OF GAMMA HYDROXYBUTYRATE WITH MONOCARBOXYLATE TRANSPORTERS | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2021-07-15 | — | — | US | disclosed |
| US-20210128502-A1 | METHOD OF ADMINISTRATION OF GAMMA HYDROXYBUTYRATE WITH MONOCARBOXYLATE TRANSPORTERS | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2021-05-06 | — | — | US | disclosed |
| US-10864181-B2 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2020-12-15 | — | — | US | disclosed |
| EP-3695833-A1 | ADMINISTRATION OF GAMMA HYDROXYBUTYRATE WITH MONOCARBOXYLATE TRANSPORTERS | Jazz Pharmaceuticals Ireland Limited (IE) | 2020-08-19 | — | — | EP | disclosed |
| US-6103537-A | Capillary assays involving separation of free and bound species | ACLARA BIOSCIENCES, INC. (US) | 2000-08-15 | — | — | US | disclosed |
| WO-1999018438-A1 | CAPILLARY ASSAYS INVOLVING SEPARATION OF FREE AND BOUND SPECIES | ACLARA BIOSCIENCES, INC. (US) | 1999-04-15 | — | — | WO | disclosed |
| US-RE35517-E | PROGESTERONE DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1997-05-20 | — | — | US | disclosed |
| US-5550021-A | USING DNA SAMPLE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-08-27 | — | — | US | disclosed |
| EP-0527962-A4 | METHOD, COMPOSITIONS, AND COMPOUNDS FOR MODULATING BRAIN EXCITABILITY | — | 1993-10-20 | — | — | EP | disclosed |
| US-5208227-A | Stress relieving and anxiety modulators | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1993-05-04 | — | — | US | disclosed |
| EP-0527962-A1 | METHOD, COMPOSITIONS, AND COMPOUNDS FOR MODULATING BRAIN EXCITABILITY | GEE, Kelvin W. (US) | 1993-02-24 | — | — | EP | disclosed |
| US-5120723-A | Alleviate stress, anxiety, seizures | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1992-06-09 | — | — | US | disclosed |
| WO-1991016897-A1 | METHOD, COMPOSITIONS, AND COMPOUNDS FOR MODULATING BRAIN EXCITABILITY | WELLMAN GEE KELVIN (US) | 1991-11-14 | — | — | WO | disclosed |